Search Result

Results for "

structural analogue

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Cannabinoid Receptor (1) CETP (1) Drug Metabolite (1) Endogenous Metabolite (5) Epigenetic Reader Domain (1) Flavivirus (1) Fluorescent Dye (1) GABA Receptor (1) GPR55 (1) Isotope-Labeled Compounds (1) Molecular Glues (1) Parasite (1) Potassium Channel (3) Prostaglandin Receptor (1) Ras (1) TNF Receptor (3) Topoisomerase (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (3) Endocrinology (2) Infection (5) Metabolic Disease (2) Neurological Disease (9)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50848

BW A868C	Prostaglandin Receptor	Cardiovascular Disease
BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP) .

HY-150102

EPI-7170	Androgen Receptor	Cancer
EPI-7170, a ralaniten analogue, is a potent *androgen receptor N-terminal structural* domain** antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) .

HY-Y1373

Cyclohexanecarboxylic acid Hexahydrobenzoic acid	Endogenous Metabolite	Neurological Disease
Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .

HY-15966A

GSK2110183 analog 1 hydrochloride	Akt	Cancer
GSK2110183 analog 1 hydrochloride is the structural analogue of GSK2110183.

HY-131583

MP265 4-Chlorobenzyl carbamimidothioate hydrochloride	Others	Infection
MP265 (4-Chlorobenzyl carbamimidothioate hydrochloride) is a structural analogue of A22 but is less toxic. MP265 is a MreB inhibitor .

HY-15966

GSK2110183 analog 1	Akt	Cancer
GSK2110183 analog 1 is the structural analogue of GSK2110183.

HY-103503

CGP13501	GABA Receptor	Neurological Disease
CGP13501 is a positive allosteric modulator of GABAB receptor. CGP13501 is a structural analogue of propofol .

HY-N12519

1,2-Didehydrocryptotanshinone	Others	Others
1,2-Didehydrocryptotanshinone is a structural analogue of cryptotanshinone (CT) (HY-N0174) .

HY-128977

CD235	Epigenetic Reader Domain	Cancer
CD235 is a structurally similar analogue of CD161. CD161 is a potent and orally bioavailable BET bromodomain inhibitor .

HY-Y1373R

Cyclohexanecarboxylic acid (Standard)	Endogenous Metabolite	Neurological Disease
Cyclohexanecarboxylic acid (Standard) is the analytical standard of Cyclohexanecarboxylic acid. This product is intended for research and analytical applications. Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action .

HY-Y1373S

Cyclohexanecarboxylic acid-d1	Endogenous Metabolite	Neurological Disease
Cyclohexanecarboxylic acid-d₁ is the deuterium labeled Cyclohexanecarboxylic acid[1]. Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action[2].

HY-Y1373S1

Cyclohexanecarboxylic acid-d11	Endogenous Metabolite	Neurological Disease
Cyclohexanecarboxylic acid-d₁₁ is the deuterium labeled Cyclohexanecarboxylic acid[1]. Cyclohexanecarboxylic acid is a Valproate structural analogue with anticonvulsant action[2].

HY-106662

Chloroquinoxaline sulfonamide Chloroquinoxaline; NSC-339004	Molecular Glues Topoisomerase Parasite	Infection Cancer
Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle . Antitumor activity .

HY-Y1129

3-Hydroxypyridine	Others	Others
3-Hydroxypyridine is isolated from Bamboo grass. 3-Hydroxypyridine derivatives are structural analogues of vitamin B6 and have a wide range of pharmacological properties, such as antioxidant properties .

HY-123239

KLS-13019	GPR55	Neurological Disease
KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats .

HY-123039

CP-532623	CETP	Metabolic Disease
CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .

HY-124013

NBDA 4-(α-N-L-alanine)-NBD	Fluorescent Dye	Others
NBDA (4-(α-N-L-alanine)-NBD) is a structural and functional analogue of the 2,4-dinitrophenyl group (DNP). NBDA can be used to detect and characterize antinitroaromatic antibodies, even in crude preparations, and possibly on cell surfaces .

HY-112140

JH-VIII-157-02	Anaplastic lymphoma kinase (ALK)	Cancer
JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC₅₀ of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.

HY-153723

BI-2493	Ras	Cancer
BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research .

HY-101445B

(S)-Trolox	Others	Neurological Disease
(S)-Trolox is an analogue of vitamin E, in which the phytyl chain is replaced with a carboxyl group. (S)-Trolox is frequently used as a model compound for studies of structural features, as well as a standard for evaluation of antioxidant activity. (S)-Trolox has potent and specific neuroprotective and antioxidant effects .

HY-113329

Guanidinoethyl sulfonate Taurocyamine	Endogenous Metabolite	Metabolic Disease
Guanidinoethyl sulfonate (Taurocyamine), a transport antagonist of taurine, induces much urinary taurine excretion with a resulting decrease in the tissue taurine content and readily produces taurine-deficient fetal rats in pregnant rats . Guanidinoethyl sulfonate, a structural analogue of taurine, acts as a competitive inhibitor of taurine transport .

HY-120954

14,15-EE-5(Z)-E	Others	Cardiovascular Disease
14,15-EE-5(Z)-E is a structural analogue of 14, 15-epoxide dicartrienoic acid (14,15-EET). 14,15-EE-5(Z)-E antagonizes the relaxation of vascular smooth muscle induced by EET .

HY-131606B

Cidofovir diphosphate tri(triethylamine)	Drug Metabolite	Infection
Cidofovir diphosphate tri triethylamine is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate tri triethylamine is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

HY-131606

Cidofovir diphosphate	Others	Infection
Cidofovir diphosphate is an active intracellular metabolite of Cidofovir. Cidofovir diphosphate is a selective inhibitor of viral DNA polymerases with K_i values of 6.6, 0.86 and 1.4 μM for HCMV, HSV-1 and HSV-2 DNA polymerase, respectively .

HY-Y1129S

3-Hydroxypyridine-d4	Isotope-Labeled Compounds	Others
3-Hydroxypyridine-d₄ is the deuterium labeled 3-Hydroxypyridine[1]. 3-Hydroxypyridine is isolated from Bamboo grass. 3-Hydroxypyridine derivatives are structural analogues of vitamin B6 and have a wide range of pharmacological properties, such as antioxidant properties[2][3].

HY-100197

Synaptamide 1 Publications Verification N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide	Cannabinoid Receptor	Neurological Disease
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

HY-15643

LY 303511	TNF Receptor Potassium Channel	Cancer
LY303511 is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K ⁺ currents (IC₅₀=64.6±9.1 μM) in MIN6 insulinoma cells.

HY-15643A

LY 303511 hydrochloride 2 Publications Verification	TNF Receptor Potassium Channel	Cancer
LY 303511 hydrochloride is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K ⁺ currents (IC₅₀=64.6±9.1 μM) in MIN6 insulinoma cells.

HY-15643B

LY 303511 dihydrochloride	TNF Receptor Potassium Channel	Cancer
LY 303511 dihydrochloride is a structural analogue of LY294002. LY 303511 dihydrochloride does not inhibit PI3K. LY 303511 dihydrochloride enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY 303511 dihydrochloride reversibly blocks K ⁺ currents (IC₅₀=64.6±9.1 μM) in MIN6 insulinoma cells.

HY-W015764

T-1105 1 Publications Verification	Flavivirus	Infection
T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase .

Cat. No.	Product Name

HY-L044

Nucleotide Compound Library	539 compounds
Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications. MCE offers a unique collection of 539 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

Nucleotide Compound Library

539 compounds

Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications.

MCE offers a unique collection of 539 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

HY-L043

Lipid Compound Library	1,439 compounds
Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies. MCE supplies a unique collection of 1,439 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

Lipid Compound Library

1,439 compounds

Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies.

MCE supplies a unique collection of 1,439 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

HY-L0120V

Asinex BioDesign Library	170,269 compounds
“BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates. Saturated, fused ring, spiro, and bridged systems with a tendency towards multiple chiral centers are highly privileged among natural products and marketed drugs yet these structures are very poorly represented in commercial libraries. This library addressed this market need by incorporating these privileged elements into the design of novel synthetic molecules with high molecular framework diversity, multiple stereogenic centers (≥2), and degree of saturation (Fsp3 > 0.5).

Asinex BioDesign Library

170,269 compounds

“BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates.

Saturated, fused ring, spiro, and bridged systems with a tendency towards multiple chiral centers are highly privileged among natural products and marketed drugs yet these structures are very poorly represented in commercial libraries. This library addressed this market need by incorporating these privileged elements into the design of novel synthetic molecules with high molecular framework diversity, multiple stereogenic centers (≥2), and degree of saturation (Fsp3 > 0.5).

Cat. No.	Product Name	Type